BCL2 and prostate cancer: Application of lycopene to hormone-refractory prostate cancer cell lines in a dose-dependent manner has resulted in a decrease of Bcl-2 expression, an increase in Bax proteins, and induction of apoptosis by causing cycle distribution changes [25].